Development of novel evaluation method for anticancer drug susceptibility by a comprehensive analysis of drug-metabolizing enzyme expression in human lung cancer.

2015 Fiscal Year Final Research Report

• Project/Area Number: 25462187
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Respiratory surgery
• Research Institution: Hyogo Medical University
• Principal Investigator: Tsunehiro Oyama 兵庫医科大学, 医学部, 非常勤講師 (00309965)
• Co-Investigator(Kenkyū-buntansha): GOTOH Akinobu 兵庫医科大学, 医学部, 教授 (70283885)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 肺癌 / 抗癌剤 / 薬物代謝酵素 / チトクロームP450 / 抗癌剤感受性 / 癌幹細胞 / aldehyde dehydrogenase-1 / ALDH1

Outline of Final Research Achievements

Lung cancer is the leading cause of cancer death in Japan. We really need to develop a novel evaluation method for anticancer drug susceptibility. In 80 non-small cell lung cancer patients, we investigated the drug-metabolizing enzyme (Cytochrome P450: CYP), such as CYP1A1, CYP2A6, CYP2E1 and CYP3A) and their relationships to each other and clinical features of the patients. In addition, we investigated the cancer stem cell marker (aldehyde dehydrogenase-1: ALDH1) and their relationships to clinical features in 183 adenocarcinoma patients. Thus, studies of the local expression of drug-metabolizing enzyme and cancer stem cell marker in tumor tissues will provide insights into mechanisms of carcinogenesis and intra-tumor metabolisms of anticancer drugs, which may enable us to develop the present ready-made therapy to the tailor-made therapy.

Free Research Field

分子疫学, 分子腫瘍学、労働衛生学、呼吸器外科学、胸部外科学